FibroGen股价在FDA对罗沙司他治疗MDS贫血的积极反馈后大涨

英为财情
Aug 08, 2025

Investing.com -- FibroGen Inc (NASDAQ:FGEN)股价跳涨9.9%,此前美国食品药品监督管理局(FDA)给予积极反馈,支持推进罗沙司他用于治疗高红细胞输注负担的低风险骨髓增生异常综合征(LR-MDS)患者的贫血。 FDA的有利回应是在一次C类会议后给出的,会上该公司提交了其MATTERHORN第三期临床试验的事后分析数据。分析显示,在高输血负担的患者中,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10